Sector News

Boston Scientific to buy Endo’s urology portfolio for $1.65 billion

March 2, 2015
Life sciences
(Reuters) – Medical device maker Boston Scientific Corp (BSX.N) said it will buy Endo International Plc’s (ENDP.O) American Medical Systems’ men’s and prostate health business for up to $1.65 billion.
The purchase ends a nearly decade-long deal drought for Boston Scientific, which has not completed a large takeover since its 2006 acquisition of heart device maker Guidant Corp for $27 billion.
The deal value includes additional $50 million in milestone based on 2016 sales, Boston Scientific said on Monday.
AMS’ men’s and prostate health businesses, which generated 2014 sales of about $400 million, provides treatments for conditions such as erectile dysfunction, enlarged prostate and bladder leakage.
Reuters reported last week that Boston Scientific was close to buying Endo’s AMS medical device unit.
Monday’s deal, which is expected to close in the third quarter of 2015, does not include AMS’ women’s health business.
Endo said in a separate statement it is evaluating strategic alternatives for the business.
Boston Scientific said it will finance the deal through a combination of existing and newly committed credit facilities.
BofA Merrill Lynch is Endo’s financial adviser and Skadden Arps Slate Meagher & Flom LLP the legal adviser.
J.P. Morgan Securities is financial adviser to Boston Scientific.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D’Souza)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]